(18)F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors: Value to Patient Management and Survival Outcomes

PET Clin. 2015 Jul;10(3):423-30. doi: 10.1016/j.cpet.2015.03.011.

Abstract

(18)F-flourodeoxy-glucose (FDG) PET/computed tomography (CT) is most useful in the evaluation of primary central nervous system (CNS) lymphoma, important in diagnosis, pretherapy prognosis, and therapy response evaluation. Utility in working up gliomas is less effective, and FDG PET/CT is most helpful when MR imaging is unclear. FDG avidity correlates with the grade of gliomas. FDG PET/CT can be used to noninvasively identify malignant transformation. Establishing this change in the disease process has significant effects on patient management and survival outcome.

Keywords: Brain; Cancer; Central nervous system neoplasm; PET; PET/computed tomography; Patient management; Survival outcomes; Tumor.

Publication types

  • Review

MeSH terms

  • Brain Neoplasms / diagnostic imaging*
  • Brain Neoplasms / pathology
  • Early Detection of Cancer / methods
  • Fluorodeoxyglucose F18
  • Glioma / diagnostic imaging*
  • Glioma / pathology
  • Humans
  • Lymphoma / diagnostic imaging*
  • Lymphoma / pathology
  • Multimodal Imaging / methods*
  • Neoplasm Recurrence, Local / diagnostic imaging
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Staging
  • Positron-Emission Tomography / methods*
  • Precancerous Conditions / diagnostic imaging
  • Precancerous Conditions / pathology
  • Prognosis
  • Radiopharmaceuticals
  • Tomography, X-Ray Computed / methods*

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18